Ibuprofen derivative and preparation method and application thereof
Idioprofen derivative IDE-3 was developed through drug modification of ibuprofen and idebenone, which solved the problem of poor effectiveness of existing liver cancer treatment methods, achieved significant inhibition of liver cancer cell and organ growth, and provided New ideas for the development of anti-hepatitis cancer compounds, and ensure safe and low-cost production.
Patent Information
- Application Number
- CN202410965902.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-12-03
AI Technical Summary
The existing treatment methods for liver cancer are not effective, especially surgical and radiotherapy, which have limited effect on liver cancer treatment, and the toxic and side effects of existing drugs are high, resulting in urgent research on exploring new drugs and new models.
Through drug modifications based on ibuprofen and idebenone, a novel ibuprofen derivative IDE-3 was developed, which is a compound that promotes and migrates the proliferation and migration of liver cancer cell lines Hep3B, Huh7 and human hepatocellular carcinoma organoid growth It has significant inhibitory effect, simple preparation method and high safety.
IDE-3 is significantly better than the parent nucleus compounds ibuprofen and idebenone, and shows stronger activity in inhibiting the proliferation, migration and organ growth of liver cancer cells, providing new ideas and ways to develop anti-hepatitis cancer compounds, while ensuring Low toxicity and low economic burden.
Smart Images

Figure CN119059912A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to an ibuprofen derivative and a preparation method and application thereof. Background Art
[0002] Hepatocellular carcinoma (HCC) is a malignant tumor that begins in the liver and can be divided into two types: primary and secondary. Among them, primary liver cancer is the sixth most common type of cancer in the world, with a high mortality rate, and is also a serious public health problem facing my country. In recent years, with the joint efforts of experts and scholars at home and abroad, a variety of new treatment methods have emerged in the clinical treatment of liver cancer, including surgical treatment, radiotherapy and systemic drug therapy, which have greatly improved the treatment effect. However, the expansion of surgical indications is not smooth sailing, and other treatments need to be combined to ensure the efficacy. In addition, radiotherapy and systemic chemotherapy are not effective in treating liver cancer. Even though clinical research on drugs for the treatment of liver cancer has been reported frequently in recent years, the burden of liver cancer on my country and even the world is still heavy. Therefore, research on exploring new drugs, new models, and new solutions has been ongoing, and broad benefits, lower toxicity, and less economic burden have always been the common goals pursued by experts and scholars.
[0003] Ibuprofen is a non-steroidal anti-inflammatory drug with antipyretic, analgesic, anti-inflammatory and anti-rheumatic effects. It is a commonly used clinical drug with good safety. Idebenone has the effects of activating mitochondrial respiratory activity, increasing ATP production in myocardial cells, reducing oxidative stress, and inhibiting inflammatory responses. It is one of the most effective antioxidants in clinical use and is used to treat patients with brain function damage and mental and behavioral disorders related to cerebrovascular disease, and has low toxic and side effects. Therefore, it is of great practical significance and development value to modify drugs based on ibuprofen and idebenone and explore more therapeutic effects of their derivatives. At present, there are few reports on the anti-tumor research of ibuprofen, idebenone and their derivatives. Summary of the invention
[0004] The purpose of the present invention is to provide an ibuprofen derivative and a preparation method thereof in view of the deficiencies in the prior art. The ibuprofen derivative has a good inhibitory effect on the proliferation and migration of liver cancer cell lines Hep3B and Huh7 and the growth of human hepatocellular carcinoma organoids, which is significantly stronger than the parent core compounds ibuprofen and idebenone, and has good development value. The technology also provides new ideas and approaches for the synthesis and development of anti-liver cancer compounds, and the preparation process is simple.
[0005] The technical solution of the present invention is as follows:
[0006] An ibuprofen derivative, characterized in that its structural formula is as follows:
[0007]
[0008] The preparation method of the ibuprofen derivative as described above comprises the following steps:
[0009] (1) dissolving ibuprofen in acetonitrile, stirring to dissolve, and setting aside;
[0010] (2) Take N,N'-dicyclohexylcarbodiimide, add acetonitrile, stir to dissolve, and set aside;
[0011] (3) adding idebenone and 4-dimethylaminopyridine to the solution of step (1), stirring to dissolve;
[0012] (4) adding the solution obtained in step (2) to the solution in step (3), stirring, and reacting at room temperature;
[0013] (5) Take the reaction solution obtained in step (4), add water, then add ethyl acetate for extraction, combine the organic phases, dry with Na2SO4, filter, and concentrate the filtrate to dryness;
[0014] (6) The concentrate obtained in step (5) is applied to a silica gel column for elution, the eluate is collected, and evaporated to dryness to obtain a yellow solid, which is an ibuprofen derivative.
[0015] Furthermore, in the above-mentioned method for preparing the ibuprofen derivative, the amount of ibuprofen used in step (1) is 61 mg, and the amount of acetonitrile used is 2 mL.
[0016] Furthermore, in the above-mentioned method for preparing ibuprofen derivatives, the amount of N,N'-dicyclohexylcarbodiimide used in step (2) is 91.4 mg, and the amount of acetonitrile added is 1 mL.
[0017] Furthermore, in the above-mentioned method for preparing ibuprofen derivatives, the amount of idebenone added in step (3) is 100 mg, and the amount of 4-dimethylaminopyridine added is 3.6 mg.
[0018] Furthermore, in the above-mentioned method for preparing ibuprofen derivatives, the reaction time in step (4) is 2 hours.
[0019] Furthermore, in the above-mentioned method for preparing ibuprofen derivatives, the amount of water added in step (5) is 10 mL, and the extraction with ethyl acetate is performed by adding ethyl acetate for extraction three times, each time with 10 mL.
[0020] Furthermore, in the above-mentioned method for preparing ibuprofen derivatives, the eluent in step (6) is a solution with a volume ratio of petroleum ether:ethyl acetate = 6:1.
[0021] The application of the ibuprofen derivatives as described above is in the preparation of anti-liver cancer drugs.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] 1. The present invention provides a class of novel structural compounds - ibuprofen derivative IDE-3, which has strong inhibitory activity on the proliferation and migration of liver cancer cell lines Hep3B and Huh7 and the growth of human hepatocellular carcinoma organoids, and its activity is significantly better than that of the parent core compounds ibuprofen and idebenone, and has great development value. This technology also provides new ideas and approaches for the synthesis and development of anti-liver cancer compounds.
[0024] 2. The present invention uses ibuprofen and idebenone, currently commonly used drugs in clinical practice, as the parent core. These two drugs have low toxicity and side effects and good safety, which effectively ensures the safety of the product of the present invention.
[0025] 3. The preparation method of the present invention is simple, has no special requirements on production equipment, is easy to operate, has low cost, and is easy to realize industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The graph shows the experimental results of the effects of ibuprofen, idebenone and IDE-3 on the clone formation of human liver cancer cell Huh7, where A is the control group; B is the ibuprofen group; C is the idebenone group; and D is the IDE-3 group.
[0027] Figure 2 The graph shows the experimental results of the effects of ibuprofen, idebenone and IDE-3 on the migration of human liver cancer cells Huh7, where A is the control group; B is the ibuprofen group; C is the idebenone group; and D is the IDE-3 group.
[0028] Figure 3 This is a graph showing the experimental results of the effects of ibuprofen, idebenone and IDE-3 on the growth of human hepatocellular carcinoma organoids, where A is the control group; B is the ibuprofen group; C is the idebenone group; and D is the IDE-3 group. DETAILED DESCRIPTION
[0029] The present invention is further described below in conjunction with specific embodiments, but the protection scope and application scope of the present invention are not limited:
[0030] 1. Preparation of an ibuprofen derivative
[0031] Example 1
[0032] A method for preparing an ibuprofen derivative comprises the following steps:
[0033]
[0034] (1) Dissolve 61 mg of ibuprofen in 2 mL of acetonitrile, stir until dissolved, and set aside;
[0035] (2) Take 91.4 mg of N,N'-dicyclohexylcarbodiimide, add 1 mL of acetonitrile, stir to dissolve, and set aside;
[0036] (3) Add 100 mg of idebenone and 3.6 mg of 4-dimethylaminopyridine to the solution in step (1), and stir to dissolve;
[0037] (4) adding the solution obtained in step (2) to the solution in step (3), stirring, and reacting at room temperature for 2 hours;
[0038] (5) Take the reaction solution obtained in step (4), add 10 mL of water, and then add ethyl acetate to extract 3 times, 10 mL each time, combine the organic phases, dry with Na2SO4, filter, and concentrate the filtrate to dryness;
[0039] (6) The concentrate obtained in step (5) was loaded onto a silica gel column and eluted with a solution having a volume ratio of petroleum ether:ethyl acetate = 6:1. The eluate was collected and evaporated to dryness to obtain a yellow solid (petroleum ether / EtOAc, 8:1) IDE-3 (133.7 mg, 86%), Rf = 0.75 (petroleum ether / ethyl acetate, 4:1).
[0040] The structure confirmation results of the prepared compound IDE-3 are as follows:
[0041] 1 H NMR (400MHz, CDCl3) δ7.19(d,J=8.1Hz,2H),7.08(d,J=8.1Hz,2H),4.04(t,J=6.6 Hz,2H),3.98(d,J=1.1Hz,6H),3.67(q,J=7.2Hz,1H),2.51-2.41(m,4H),2.00(s, 3H),1.89-1.77(m,1H),1.55(t,J=6.6Hz,2H),1.47(d,J=7.2Hz,3H),1.39-1.34( m,2H),1.33(d,J=6.0Hz,2H),1.25(m,2H),1.22(m,8H),0.89(s,3H),0.87(s,3H); 13 C NMR (100MHz, CDCl3) δ184.69,184.12,174.81,144.22,143.02,140.38,138.62,137.85,129.21,127.10,64.72,61.12,4 5.14,44.98,30.15,29.79,29.40,29.36,29.30,29.09,28.70,28.46,26.35,25.70,22.34,18.43,11.88.MS(ESI):[M+H]+ 527.4. HPLC purity (99.36%).
[0042] 2. Pharmacology and efficacy tests
[0043] Example 2
[0044] Effect of IDE-3 on the proliferation of human hepatocellular carcinoma cell line Hep3B
[0045] 1. Experimental Materials
[0046] 1.1 Cell line: Human liver cancer cell line Hep3B
[0047] 1.2 Reagents and instruments: MEM basal medium (Wuhan Punosai Life Science Co., Ltd.), fetal bovine serum (FBS; Wuhan Punosai Life Science Co., Ltd.), 0.25% trypsin (GIBCO), penicillin-streptomycin (GIBCO), dimethyl sulfoxide (DMSO, Sigma), CCK-8 detection kit (Japan Dojin Chemical Research Institute), Synergy TM H1 multifunctional microplate reader (BioTek), clean bench (Singapore Yisi High-Tech Co., Ltd.), constant temperature water bath (Shanghai Jinghong Experimental Equipment Co., Ltd.), low-speed centrifuge (Hunan Hengnuo Instrument Equipment Co., Ltd.), cell culture incubator (Singapore Yisi High-Tech Co., Ltd.).
[0048] 2. Experimental Methods
[0049] 2.1 Culture Hep3B cells. Digest and collect cells with 0.25% trypsin, centrifuge at 1200 rpm for 5 minutes, resuspend the cell pellet with MEM basal medium containing 10% FBS, inoculate at a density of 3000 cells / well in a 96-well culture plate (100 μL volume), and then culture in a common cell culture incubator at 37°C, 5% CO2 and saturated humidity.
[0050] 2.2 Each group was treated with drugs according to the following conditions and then cultured for 48 hours.
[0051] Control group: the group without medication.
[0052] Positive control group: The ibuprofen group and idebenone group were divided into 3 groups, a total of 6 groups:
[0053] Positive control group 1: ibuprofen was added at a final concentration of 10 μM.
[0054] Positive control group 2: ibuprofen was added at a final concentration of 20 μM.
[0055] Positive control group 3: ibuprofen was added at a final concentration of 40 μM.
[0056] Positive control group 4: Idebenone was added at a final concentration of 10 μM.
[0057] Positive control group 5: Idebenone was added at a final concentration of 20 μM.
[0058] Positive control group 6: Idebenone was added at a final concentration of 40 μM.
[0059] IDE-3 Group: The IDE-3 group is divided into 3 groups:
[0060] IDE-3 group 1: Add IDE-3 at a final concentration of 10 μM.
[0061] IDE-3 Group 2: Add IDE-3 at a final concentration of 20 μM.
[0062] IDE-3 Group 3: Add IDE-3 at a final concentration of 40 μM.
[0063] After intervening Hep3B cells under the above conditions, the CCK-8 kit was used to detect the effect of the drug on the proliferation of Hep3B cells. The specific operation was as follows: 10 μL CCK-8 was added to each well, and the absorbance value at a wavelength of 450 nm was measured using an ELISA instrument after continued culture for 1.5 hours. The cell proliferation inhibition rate of each group was calculated based on the cell proliferation inhibition rate of 0% in the control group.
[0064] 3. Experimental results
[0065] Table 1 Effect of IDE-3 on the proliferation of human hepatoma cell line Hep3B
[0066]
[0067] As shown in Table 1, IDE-3 can significantly inhibit the proliferation of human liver cancer cell line Hep3B, and its inhibitory effect increases with increasing dose, that is, it is dose-dependent; and its inhibitory effect is significantly better than that of positive control drugs ibuprofen and idebenone.
[0068] Example 3
[0069] Effect of IDE-3 on the clone formation of human hepatocellular carcinoma cell line Huh7
[0070] 1. Experimental Materials
[0071] 1.1 Cell line: Human hepatoma cell line Huh7
[0072] 1.2 Reagents and instruments: MEM basal medium (Wuhan Pronosai Life Science Technology Co., Ltd.), fetal bovine serum (FBS; Wuhan Pronosai Life Science Technology Co., Ltd.), 0.25% trypsin (GIBCO), penicillin-streptomycin (GIBCO), dimethyl sulfoxide (DMSO, Sigma), clean bench (Singapore Yisi High-Tech Co., Ltd.), constant temperature water bath (Shanghai Jinghong Experimental Equipment Co., Ltd.), low-speed centrifuge (Hunan Hengnuo Instrument Equipment Co., Ltd.), cell culture incubator (Singapore Yisi High-Tech Co., Ltd.).
[0073] 2. Experimental Methods
[0074] 2.1 Culture Huh7 cells. Digest and collect cells with 0.25% trypsin, centrifuge at 1200 rpm for 5 minutes, resuspend the cell pellet with MEM basal medium containing 10% FBS, inoculate the cells at a density of 1000 cells / well in a 6-well culture plate, and then culture in a common cell culture incubator at 37°C, 5% CO2 and saturated humidity.
[0075] 2.2 Each group was treated with drugs according to the following conditions and then cultured for 5 more days.
[0076] Control group: the group without medication.
[0077] Positive control group: The ibuprofen group and the idebenone group were divided into 1 group each, for a total of 2 groups:
[0078] Positive control group 1: ibuprofen was added at a final concentration of 20 μM.
[0079] Positive control group 2: Idebenone was added at a final concentration of 20 μM.
[0080] IDE-3 group: IDE-3 was added at a final concentration of 20 μM.
[0081] After Huh7 cells were treated under the above conditions for 5 days, they were fixed with 4% paraformaldehyde for 15 minutes and stained with crystal violet for 30 minutes. The cell clone formation in each group was recorded by taking photos.
[0082] 3. Experimental results
[0083] like Figure 1 As shown, IDE-3 can significantly inhibit the cloning of human liver cancer cell line Huh7, and the inhibitory effect is significantly better than that of positive control drugs ibuprofen and idebenone.
[0084] Example 4
[0085] Effect of IDE-3 on migration of human hepatoma cell line Huh7
[0086] 1. Experimental Materials
[0087] 1.1 Cell line: Human hepatoma cell line Huh7
[0088] 1.2 Reagents and instruments: MEM basal medium (Wuhan Pronosai Life Science Technology Co., Ltd.), fetal bovine serum (FBS; Wuhan Pronosai Life Science Technology Co., Ltd.), 0.25% trypsin (GIBCO), penicillin-streptomycin (GIBCO), dimethyl sulfoxide (DMSO, Sigma), clean bench (Singapore Yisi High-Tech Co., Ltd.), constant temperature water bath (Shanghai Jinghong Experimental Equipment Co., Ltd.), low-speed centrifuge (Hunan Hengnuo Instrument Equipment Co., Ltd.), cell culture incubator (Singapore Yisi High-Tech Co., Ltd.).
[0089] 2. Experimental Methods
[0090] 2.1 Culture Huh7 cells, digest and collect cells with 0.25% trypsin, centrifuge at 1200 rpm for 5 minutes, resuspend the cell pellet with MEM basal medium containing 10% FBS, inoculate at a density of 300,000 cells / well in a 6-well culture plate, and then culture in a common cell culture incubator at 37°C, 5% CO2 and saturated humidity.
[0091] 2.2 Each group was treated with drugs according to the following conditions and then cultured for 48 hours.
[0092] Control group: the group without medication.
[0093] Positive control group: The ibuprofen group and the idebenone group were divided into 1 group each, for a total of 2 groups:
[0094] Positive control group 1: ibuprofen was added at a final concentration of 40 μM.
[0095] Positive control group 2: Idebenone was added at a final concentration of 40 μM.
[0096] IDE-3 group: IDE-3 was added at a final concentration of 40 μM.
[0097] After Huh7 cells were treated under the above conditions, the cells were collected, resuspended in serum-free medium and inoculated in Transwell chambers, and the culture medium in the lower chamber was MEM medium containing 10% serum. After 24 hours, the chambers were taken out, fixed with methanol for 10 minutes, and stained with crystal violet for 30 minutes, and the migration of cells in each group was recorded by taking pictures.
[0098] 3. Experimental results
[0099] like Figure 2As shown, IDE-3 can significantly inhibit the migration of human liver cancer cell line Huh7, and the inhibitory effect is significantly better than that of positive control drugs ibuprofen and idebenone.
[0100] Example 5
[0101] Effects of IDE-3 on the growth of human hepatocellular carcinoma organoids
[0102] 1. Experimental Materials
[0103] 1.1 Organoids: Human hepatocellular carcinoma organoids
[0104] 1.2 Reagents and instruments: Hepatocellular carcinoma organoid culture medium (Shanghai Xinchao Biotechnology Co., Ltd.), organoid digestion solution (Shanghai Xinchao Biotechnology Co., Ltd.), organoid freezing solution (Shanghai Xinchao Biotechnology Co., Ltd.), fetal bovine serum (FBS; BI Company), MEM basal medium (Wuhan Prosai Life Science Co., Ltd.), low growth factor matrix gel (Corning Company), clean bench (Singapore Yisi High Technology Co., Ltd.), constant temperature water bath (Shanghai Jinghong Experimental Equipment Co., Ltd.), low-speed centrifuge (Hunan Hengnuo Instrument Equipment Co., Ltd.), cell culture incubator (Singapore Yisi High Technology Co., Ltd.).
[0105] 2. Experimental Methods
[0106] 2.1 Cultivate human hepatocellular carcinoma organoids, digest with organoid digestion solution for 5 minutes, terminate digestion with MEM basal medium containing 10% FBS, and centrifuge at 1000 rpm for 5 minutes. Resuspend the cell pellet with organoid medium, inoculate at a density of 1000 cells / well in a 96-well culture plate (100 μL volume), and then place in a common cell culture incubator at 37°C, 5% CO2 and saturated humidity.
[0107] 2.2 Each group was treated with drugs according to the following conditions and then cultured for 5 more days.
[0108] Control group: the group without medication.
[0109] Positive control group: The ibuprofen group and the idebenone group were divided into 1 group each, for a total of 2 groups:
[0110] Positive control group 1: ibuprofen was added at a final concentration of 40 μM.
[0111] Positive control group 2: Idebenone was added at a final concentration of 40 μM.
[0112] IDE-3 group: IDE-3 was added at a final concentration of 40 μM.
[0113] After 5 days of intervention in hepatocellular carcinoma organoids under the above conditions, the growth of the organoids was observed under a microscope.
[0114] 3. Experimental results
[0115] like Figure 3 As shown, IDE-3 can significantly inhibit the number and size of human hepatocellular carcinoma organoids, and the inhibitory effect is significantly better than that of the positive control drugs ibuprofen and idebenone.
Claims
1. An ibuprofen derivative, characterized in that Its structural formula is as follows:
2. The method for preparing the ibuprofen derivative according to claim 1, wherein The following steps are involved: (1) dissolving ibuprofen in acetonitrile, stirring to dissolve, and setting aside; (2) Take N,N'-dicyclohexylcarbodiimide, add acetonitrile, stir to dissolve, and set aside; (3) adding idebenone and 4-dimethylaminopyridine to the solution of step (1), stirring to dissolve; (4) adding the solution obtained in step (2) to the solution in step (3), stirring, and reacting at room temperature; (5) Take the reaction solution obtained in step (4), add water, then add ethyl acetate for extraction, combine the organic phases, dry with Na2SO4, filter, and concentrate the filtrate to dryness; (6) The concentrate obtained in step (5) is applied to a silica gel column for elution, the eluate is collected, and evaporated to dryness to obtain a yellow solid, which is an ibuprofen derivative.
3. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: The amount of ibuprofen used in step (1) is 61 mg, and the amount of acetonitrile used is 2 mL.
4. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: In step (2), the amount of N,N'-dicyclohexylcarbodiimide used is 91.4 mg, and the amount of acetonitrile added is 1 mL.
5. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: In step (3), the amount of idebenone added is 100 mg, and the amount of 4-dimethylaminopyridine added is 3.6 mg.
6. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: The reaction time of step (4) is 2 hours.
7. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: The amount of water added in step (5) is 10 mL, and the amount of ethyl acetate added for extraction is 3 times, 10 mL each time.
8. The method for preparing the ibuprofen derivative according to claim 2, characterized in that: The eluent in step (6) is a solution with a volume ratio of petroleum ether:ethyl acetate = 6:
1.
9. The use of the ibuprofen derivative according to claim 1, characterized in that: The application is application in the preparation of anti-liver cancer drugs.
Citation Information
Cited By
Ibuprofen-desloratadine conjugate as well as preparation method and application thereof
CN122444689A
Ibuprofen-diclometisone conjugate, its preparation method and application
CN122444689B
